GHRP-2 spray is an artificially synthesized hexapeptide compound that stimulates the pulsatile secretion of endogenous growth hormone (GH) by activating the ghrelin receptor (GHS-R1a) in the hypothalamic pituitary axis, mimicking the action of natural ghrelin. As a second-generation growth hormone secretagogue (GHS), it has been widely studied in medical, sports, anti-aging and other fields due to its unique physiological activity. 2-trifluoroethyl)thiazole as a new form of preparation, attempts to achieve breakthroughs in improving bioavailability, simplifying operation process and reducing side effects through nasal administration.
Pralmorelin COA
1. Medical scenario: Core treatment for growth hormone deficiency
Children's dwarfism: GHRP-2 spray can stimulate pituitary gland to secrete GH, promote chondrocyte proliferation of bone growth plate, prolong bone age delay and improve final height. A clinical study in Japan showed that after continuous use for 6 months, the annual growth rate of children increased by 2.3cm compared to the control group.
Adult GH deficiency: Targeting GH deficiency caused by pituitary injury or disease, it can improve muscle mass, reduce body fat, and optimize metabolic indicators such as blood lipids and blood sugar. In 2012, Sella Pharmaceuticals was approved to sell 2-trifluoroethyl)thiazole nasal spray for such indications.
Postoperative recovery: By promoting collagen synthetise and immune cell activation, it accelerates wound healing and reduces the risk of infection. For example, in patients after joint replacement, combined use of product can shorten the healing time by 30%.
Anti aging scenario: potential intervention measures to delay physiological decline
Skin rejuvenation: stimulates collagen synthetise, increases skin thickness and elasticity, and reduces wrinkle formation. Combined use of antioxidants (such as vitamin C) can significantly improve skin firmness.
Bone density maintenance: By promoting osteoblast activity, inhibiting osteoclast differentiation, and reducing the risk of osteoporosis. It has a protective effect on the bone health of the elderly population or long-term hormone users (such as glucocorticoids).
Cognitive function protection: Animal experiments show that it can reduce the deposition of β - amyloid protein and delay the progress of Alzheimer's disease. It improves memory and cognitive function by optimizing cerebral blood flow and neuronal metabolism.
Breakthrough and Challenge in Nasal Drug Delivery
Traditional GHRP-2 spray formulations are mainly injectable, but there are problems such as complex operation, pain, and local infection risk. The aerosol type is absorbed by the nasal mucosa, trying to achieve improvement in the following aspects:
The nasal mucosa has abundant blood supply, and drugs can directly enter the systemic circulation, bypassing the first pass effect. Research has shown that the bioavailability of 2-trifluoroethyl)thiazole nasal administration can reach 53%, much higher than oral administration (0.3-1%), although still lower than injection (100%), it significantly simplifies the operation process.
The spray type can rapidly penetrate into the mucosa and shorten the onset time of the drug. In animal experiments, the peak time of GH during nasal administration is 15-20 minutes earlier than that of injection, which is suitable for scenarios that require rapid increase in GH levels (such as postoperative recovery).
The spray type does not need injection tools, and is easy to operate, especially suitable for children, the elderly or patients who are afraid of injection. For example, 2-trifluoroethyl)thiazole (trade name: GHRP Kaken Nasal) developed by Japanese Kaken Pharma Company has been approved for the treatment of growth hormone deficiency in children.
The spray device can realize single dose standardization (such as 100mcg per spray) through the pump head design, reduce human error and improve treatment safety.
Challenges and limitations:
Mucosal irritation:
High concentrations of 2-trifluoroethyl)thiazole may cause adverse reactions such as burning sensation and sneezing in the nasal cavity. It is necessary to optimize excipients (such as adding hyaluronic acid) to reduce irritation.
Individualization of dosage:
Nasal mucosal absorption is significantly affected by individual differences (such as mucosal thickness and blood flow), and dosage needs to be adjusted through blood drug concentration monitoring.
Long term stability:
The aerosol type is sensitive to pH and temperature, and strict storage conditions (such as 2-8 ℃ cold storage) are required to prevent peptide chain degradation.
Frontier research and application expansion
In the field of anti-aging, a double-blind trial published in Nature Aging in 2024 showed that continuous use of 2-trifluoroethyl)thiazole (200mcg/day) for 6 months in elderly people aged 65 and above can increase telomerase activity by 18%, muscle strength (grip strength) by 12%, and cognitive function (MMSE score) by 2.1 points (P<0.05).
Trauma repair: In burn patients, 2-trifluoroethyl)thiazole combined with local insulin therapy can shorten wound healing time by 30% and reduce scar formation rate by 45%. The mechanism is related to GH promoting collagen synthetise and angiogenesis.
High altitude adaptation: Professional athletes using 2-trifluoroethyl)thiazole (300mcg/day) at an altitude of 2500 meters can increase blood oxygen saturation (SpO2) from 88% to 92% and maximum oxygen uptake (VO2max) by 7%.
Future prospects:
Innovative directions from single formulations to combination therapies
Targeted delivery system:
Develop new carriers such as nanoparticles and liposomes, improve the mucosal penetration and targeting of spray, and reduce systemic side effects.
Combination therapy strategy:
Used in combination with GHRH analogs (such as Sermorelin, CJC-1295) to maximize GH release through synergistic effects, while reducing monotherapy dose and risk of side effects.
Personalized medical applications:
Develop personalized dosage plans based on genetic testing (such as GHS-R1a receptor polymorphism) to optimize treatment efficacy and safety.
As a new preparation, GHRP-2 spray shows potential in improving bioavailability and simplifying operation process through nasal administration, but its application still needs to strictly follow medical norms and balance efficacy and safety. In the future, with the progress of preparation technology and the deepening of clinical research, it is expected to play a greater role in the treatment of growth hormone deficiency, postoperative rehabilitation, anti-aging and other fields. At the same time, we need to be alert to the risk of its abuse in sports stimulants, and maintain the fairness of sports competition.
The Development History of GHRP-2
Background: In the late 1970s to early 1980s, scientists synthesized purified growth hormone releasing peptide (GHRP) for the first time based on the structure of methionine leucine enkephalin. Subsequently, several types of GHRPs were synthesized, laying the foundation for the discovery of GHRP-2.
Discovery process: In 1993, Dr. CY Bowers from Durham University made a key breakthrough in the field of growth hormone secretagogue and discovered a hexapeptide compound GHRP-2 (also known as KP-102, drug name Pralmorelin). This compound stimulates the release of growth hormone from the anterior pituitary gland by activating the ghrelin receptor (GHSR-1a), mimicking the action of endogenous ghrelin.
Early research: It was found to have a stronger stimulating effect on growth hormone release and improve growth hormone deficiency in children. Its mechanism of action is different from that of growth hormone releasing hormone (GHRH), which can act on pituitary and hypothalamic cells, causing the secretion of growth hormone (GH) and GHRH.
Clinical trials: In some clinical trials, it has been used to treat children with short stature and has achieved significant therapeutic effects. It can stimulate the pituitary gland to release more growth hormone, promoting children's growth and development.
Drug development: Dr. Bowers collaborated with Kaken Pharmaceuticals to develop GHRP-2 drug. In 2005, Japan was the first to approve its launch under the trade name "GHRP Kaken 100" for the treatment of growth hormone deficiencies such as pituitary dwarfism. In 2012, the US FDA also approved its listing, with Sella Pharmaceuticals responsible for sales.
Multidimensional physiological effects: With the deepening of research, multidimensional physiological effects are gradually being revealed. It not only promotes the secretion of growth hormone, but also has various effects such as metabolic regulation, anti-inflammatory repair, and sleep optimization. For example, in an arthritis model, reducing serum IL-6 levels significantly improves inflammatory symptoms.
Application in the field of fitness: With more research confirming its efficacy, its application is gradually expanding from the medical field to the fitness and bodybuilding market. Athletes and fitness enthusiasts have found that it can become an important auxiliary tool during the muscle building phase by enhancing appetite and promoting muscle growth. It can increase the levels of serum auxin and IGF-1, enhance the signal expression of related mRNA in the liver and skeletal muscle, thereby promoting protein synthesis and muscle growth.
The applications in the field of anti-aging, such as improving sleep, enhancing immunity, and repairing joints, have also attracted people in need of anti-aging. It is considered a potential anti-aging drug that can delay the aging process and improve quality of life.
Abuse and regulation: However, the problem of abuse in the fields of fitness and anti-aging is gradually becoming prominent. During the 2014 Sochi Winter Olympics, the World Anti Doping Agency (WADA) will be included in the list of banned substances and specific testing will be achieved through urine analysis technology. Nevertheless, its legal use in non competitive sports continues to grow.
Future outlook (ongoing exploration)
Hot Tags: ghrp-2 spray, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale